Spelman, T. Et Al. 2015. Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , (Barcelona, Spain), 258-259.

Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., ... Belachew, S.(2015). Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS . 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) (pp.258-259). Barcelona, Spain

Spelman, T. Et Al. "Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS," 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 2015

Spelman, T. Et Al. "Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS." 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , Barcelona, Spain, pp.258-259, 2015

Spelman, T. Et Al. (2015) . "Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS." 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , Barcelona, Spain, pp.258-259.

@conferencepaper{conferencepaper, author={T. Spelman Et Al. }, title={Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS}, congress name={31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)}, city={Barcelona}, country={Spain}, year={2015}, pages={258-259} }